FDA Revises Compounding Guidance

News
Article

FDA revised the guidance after industry feedback and to clarify CGMP requirements for outsourcing facility operations.

On Jan. 22, 2020, FDA announced the publication of a revised draft guidance regarding compounders that are registered under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as outsourcing facilities and current good manufacturing practice (CGMP) requirements. The revisions were based on industry comments on the previous draft document and reflect the agency’s thoughts on the application of CGMP requirements to outsourcing facility operations. With the revised draft guidance, FDA intends to recognize the difference between outsourcing facilities and conventional drug manufacturers. The agency also, however, intends to ensure compounded drugs are safe for patients.

Specifically, the guidance details conditions under which the agency will not take regulatory action against an outsourcing facility while it continues to finalize CGMP requirements under parts 210 and 211 of the Code of Federal Regulations. The revised guidance includes considerations for non-sterile compounded drugs and distinguishes requirements between sterile compounded drugs and non-sterile compounded drugs. It also includes stability testing changes and release testing requirements.

The draft guidance applies to drugs that are compounded in accordance with section 503B of the FD&C Act. It also applies to drugs that outsourcing facilities repackage and biological products that outsourcing facilities mix, dilute, or repackage.

Source: FDA

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes